An observational study in Ulcerative Colitis, sponsored by Ferring Pharmaceuticals. Completed at 105 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-01.
Sponsored by Ferring Pharmaceuticals · Observational
The aim of the non-interventional study is to document the daily doses in acute and remission therapy, the frequence of doses (1, 2, 3 or 4 times daily), when rectal dosage forms are added and, when and how long steroids are given.
1,073 studies on the registry are indexed under Colitis; 131 are open to participants now.
This study's enrollment of 500 is above the median of 105 across 247 observational studies indexed under Colitis.
Browse Colitis studies →Ferring Pharmaceuticals is the lead sponsor of 244 studies on the registry; 4 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 13 (93%) have results posted.
Counted across the registry records on this site, refreshed daily.
Private practices
Exclusion Criteria:
Prescription habits measured by daily dose of Mesalazine
Time frame: 0 - 8 weeks
Compliance measured by questionnaire for drug intake
Time frame: 0 - 8 weeks
Quality of Life measured by EuroQol Questionnaire
Time frame: 0 - 8 weeks
Showing the first 100 of 105 sites.
This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ferring Pharmaceuticals